1. Sci Rep. 2023 Oct 10;13(1):17137. doi: 10.1038/s41598-023-44203-6.

The autophagy protein Def8 is altered in Alzheimer's disease and Aβ42-expressing 
Drosophila brains.

Oyarce-Pezoa S(1)(2)(3)(4), Rucatti GG(1)(2)(5), Muñoz-Carvajal F(1)(5), 
Sanhueza N(1), Gomez W(2)(6), Espinoza S(2), Leiva M(1), García N(1), Ponce 
DP(7), SanMartín CD(7)(8), Rojas-Rivera D(9)(10), Salvadores N(1)(11), Behrens 
MI(7)(12)(13)(14), Woehlbier U(15)(9), Calegaro-Nassif M(16)(17)(18), Sanhueza 
M(19)(20).

Author information:
(1)Center for Resilience, Adaptation and Mitigation, Universidad Mayor, Temuco, 
Chile.
(2)Laboratory of Autophagy and Neuroprotection, Vicerrectoría de Investigación, 
Universidad Mayor, Santiago, Chile.
(3)PhD Program in Biomedicine, Universidad de los Andes, Santiago, Chile.
(4)Center for Biomedical Research and Innovation (CiiB), Universidad de los 
Andes, Santiago, Chile.
(5)PhD Program in Neurobiology, Universidad Mayor, Santiago, Chile.
(6)PhD Program in Integrative Genomics, Universidad Mayor, Santiago, Chile.
(7)Centro de Investigación Clínica Aplicada (CICA), Hospital Clínico Universidad 
de Chile, Santiago, Chile.
(8)Instituto de Nutrición y Tecnología de los Alimentos (INTA), Universidad de 
Chile, Santiago, Chile.
(9)Escuela de Biotecnología, Facultad de Ciencias, Universidad Mayor, Santiago, 
Chile.
(10)Escuela de Tecnología Médica, Facultad de Medicina y Ciencias de la Salud, 
Universidad Mayor, Santiago, Chile.
(11)Escuela de Medicina, Facultad de Medicina y Ciencias de la Salud, 
Universidad Mayor, Temuco, Chile.
(12)Departamento de Neurociencia, Facultad de Medicina, Universidad de Chile, 
Santiago, Chile.
(13)Departamento de Neurología y Psiquiatría, Clínica Alemana de Santiago, 
Santiago, Chile.
(14)Departamento de Neurología y Neurocirugía, Hospital Clínico Universidad de 
Chile, Santiago, Chile.
(15)Center for Integrative Biology, Universidad Mayor, Santiago, Chile.
(16)Laboratory of Autophagy and Neuroprotection, Vicerrectoría de Investigación, 
Universidad Mayor, Santiago, Chile. melissa.calegaro@umayor.cl.
(17)Escuela de Biotecnología, Facultad de Ciencias, Universidad Mayor, Santiago, 
Chile. melissa.calegaro@umayor.cl.
(18)Escuela de Tecnología Médica, Facultad de Medicina y Ciencias de la Salud, 
Universidad Mayor, Santiago, Chile. melissa.calegaro@umayor.cl.
(19)Center for Resilience, Adaptation and Mitigation, Universidad Mayor, Temuco, 
Chile. mario.sanhueza@umayor.cl.
(20)Escuela de Medicina, Facultad de Medicina y Ciencias de la Salud, 
Universidad Mayor, Temuco, Chile. mario.sanhueza@umayor.cl.

Alzheimer's disease (AD) is the most common neurodegenerative disorder, 
characterized by protein accumulation in the brain as a main neuropathological 
hallmark. Among them, Aβ42 peptides tend to aggregate and create oligomers and 
plaques. Macroautophagy, a form of autophagy characterized by a double-membrane 
vesicle, plays a crucial role in maintaining neuronal homeostasis by degrading 
protein aggregates and dysfunctional organelles as a quality control process. 
Recently, DEF8, a relatively uncharacterized protein, has been proposed as a 
participant in vesicular traffic and autophagy pathways. We have reported 
increased DEF8 levels in lymphocytes from mild cognitive impairment (MCI) and 
early-stage AD patients and a neuronal profile in a murine transgenic AD model. 
Here, we analyzed DEF8 localization and levels in the postmortem frontal cortex 
of AD patients, finding increased levels compared to healthy controls. To 
evaluate the potential function of DEF8 in the nervous system, we performed an 
in silico assessment of its expression and network profiles, followed by an in 
vivo evaluation of a neuronal Def8 deficient model using a Drosophila 
melanogaster model of AD based on Aβ42 expression. Our findings show that DEF8 
is an essential protein for maintaining cellular homeostasis in the nervous 
system, and it is upregulated under stress conditions generated by Aβ42 
aggregation. This study suggests DEF8 as a novel actor in the physiopathology of 
AD, and its exploration may lead to new treatment avenues.

© 2023. Springer Nature Limited.

DOI: 10.1038/s41598-023-44203-6
PMCID: PMC10564863
PMID: 37816871 [Indexed for MEDLINE]

Conflict of interest statement: The authors declare no competing interests.